Major Investor Group Exits Monopar Therapeutics, Liquidating Stake

summarizeSummary

Tactic Pharma LLC and associated individuals have liquidated their beneficial ownership in Monopar Therapeutics, ceasing to be a 5% reporting group.

check_boxKey Events

• Investor Group Exits

  Tactic Pharma LLC, along with Chandler Robinson and Michael Brown, completed a liquidating distribution of their shares on January 28, 2026.

• Cease 5% Ownership

  As a result of the distribution, the reporting persons individually and collectively ceased to be beneficial owners of more than five percent of Monopar Therapeutics' common stock.

• Final 13D Amendment

  This filing represents the final amendment to their Schedule 13D, indicating a complete withdrawal from their reporting obligations for the company.

auto_awesomeAnalysis

This Schedule 13D/A marks the final amendment for Tactic Pharma LLC, Chandler Robinson, and Michael Brown, as they have completed a liquidating distribution of their holdings in Monopar Therapeutics. As a result, the reporting persons no longer collectively hold a beneficial ownership stake exceeding 5%, signaling a complete exit from their Schedule 13D reporting obligations. This significant reduction in institutional ownership could be perceived negatively by the market, indicating a loss of conviction from a previously substantial investor group.